Application No.: 10/588,485

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

## **LISTING OF CLAIMS:**

1. (currently amended): A propane-1,3-dione derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof

<del>(I)</del>

fsymbols in the formula mean as follows,

ring A: benzene which may be substituted with 1 to 3 substituent groups, wherein the substituent group is halogen, CN, lower alkyl which may be substituted with halogen, -O-lower alkyl, -CO-O- lower alkyl or amino, pyridine which may be substituted or thiophene ring, ring B: benzene or thiophene ring,

INTERVIEW Attorney Docket No.: Q96434

Application No.: 10/588,485

R<sup>1</sup>: H or CO lower alkyl,

 $R^2$ : H,  $-O-R^5$ ,  $-N(R^6)R^7$ ,  $-N_3$ ,  $-S(O)_m$ -lower alkyl,  $-S(O)_m$ - $N(R^6)R^7$ 

-S(O)<sub>m</sub>-N(R<sup>6</sup>)R<sup>7</sup>, halogen, pyridyl or imidazolyl which may be substituted,

R<sup>5</sup>: H, lower alkyl, -CO-lower alkyl which may be substituted, or -CO-O-lower alkyl which may be substituted,

R<sup>6</sup> and R<sup>7</sup>: may be the same or different from each other and each is H, lower alkyl, or CO-lower alkyl, with the proviso that R<sup>1</sup> and R<sup>2</sup> may together form dioxolane which may be substituted,

m: 0, 1 or 2,

R<sup>3</sup>: H or lower alkyl,

R<sup>401</sup> and R<sup>402</sup>: may be the same or different from each other and each is H, halogen, OH, -O-lower alkyl, or lower alkyl,

X: bond, lower alkylene which may be substituted, or cycloalkanediyl,

 $R^{101}$ ,  $R^{102}$ ,  $R^{103}$  and  $R^{104}$ : may be the same or different from one another and each is H, halogen, OH, or -O-lower alkyl which may be substituted with (aryl or heteroaryl).

- 2.-3. (canceled).
- 4. (currently amended): A propane-1,3-dione derivative represented by a general the formula (Ia) or a pharmaceutically acceptable salt thereof

INTERVIEW Attorney Docket No.: Q96434

Application No.: 10/588,485

(symbols in the formula mean as follows,

 $R^{801}$ ,  $R^{802}$  and  $R^{803}$ : may be the same or different from one another and each is H, halogen or lower alkyl,

 $R^{403}$  and  $R^{404}$ : may be the same or different from each other and each is H, halogen or lower alkyl, and,

R<sup>101</sup>, R<sup>102</sup>, R<sup>103</sup> and R<sup>104</sup>: may be the same or different from one another and each is H, halogen, OH, or -O-lower alkyl which may be substituted with (aryl or heteroaryl)).

5. (currently amended): The propane-1,3-dione derivative or a pharmaceutically acceptable salt thereof according to claim 4, which is at least one a compound selected from the group consisting of:

2-(1,3-Dihydro-2H-benzimidazol-2-ylidene)-1-[3-(1,2-dihydroxyethyl)phenyl]-3-(3,4,5-trifluorophenyl)propane-1,3-dione; 1-{2-butyl-3-[(1R)-1,2-dihydroxyethyl]phenyl}-2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-(3-fluorophenyl)propane-1,3-dione; 1-(3,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-[5-(1,2-dihydroxyethyl)-2-fluorophenyl]propane-1,3-dione; 1-(3,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-{3-[(1R)-1,2-dihydroxyethyl]2-methylphenyl}propane-1,3-dione; 2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-{3-[(1R)-1,2-dihydroxyethyl]2-methylphenyl}propane-1,3-dione; 2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-{3-[(1R)-1,2-dihydroxyethyl]2-methylphenyl}propane-1,3-dione; 2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-{3-[(1R)-1,2-dihydroxyethyl]2-methylphenyl}propane-1,3-dione; 2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-{3-[(1R)-1,2-dihydroxyethyl]2-methylphenyl}propane-1,3-dione; 2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-{3-[(1R)-1,2-dihydroxyethyl]2-methylphenyl}propane-1,3-dione; 2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-{3-[(1R)-1,2-dihydroxyethyl]2-methylphenyl}propane-1,3-dione; 2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-(3-dihydro-2H-benzimidazol-2

INTERVIEW Attorney Docket No.: Q96434

Application No.: 10/588,485

benzimidazol-2-ylidene)-1-{3-[(1R)-1,2-dihydroxyethyl]-2-methylphenyl}-3-(2fluorophenyl)propane-1,3-dione; 2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-1-[3-(1,2dihydroxyethyl)phenyl]-3-(2,3,5-trifluorophenyl)propane-1,3-dione; 2-(1,3-dihydro-2Hbenzimidazol-2-ylidene)-1-{3-[(1R)-1,2-dihydroxyethyl]-2-methylphenyl}-3-(3methylphenyl)propane-1,3-dione; 1-{2-chloro-3-[(1R)-1,2-dihydroxyethyl]phenyl}-2-(1,3dihydro-2H-benzimidazol-2-vlidene)-3-(3-fluorophenyl)propane-1,3-dione; 2-(1,3-dihydro-2Hbenzimidazol-2-ylidene)-1-{3-[(1R)-1,2-dihydroxyethyl]phenyl}-3-(3-fluorophenyl)propane-1,3-dione; 1-(3,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-[3-(1,2dihydroxyethyl)-2-fluorophenyl]propane-1,3-dione; 1-(3,5-difluorophenyl)-2-(1,3-dihydro-2Hbenzimidazol-2-ylidene)-3-[3-(1,2-dihydroxyethyl)-4-fluorophenyl]propane-1,3-dione; 1-{2chloro-3-[(1R)-1,2-dihydroxyethyl]phenyl}-3-(3,5-difluorophenyl)-2-(1,3-dihydro-2Hbenzimidazol-2-ylidene)propane-1,3-dione; 2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-1-{3-[(1R)-1,2-dihydroxyethyl]-2-fluorophenyl}-3-(3-fluorophenyl)propane-1,3-dione; and 1-{2chloro-3-[(1R)-1,2-dihydroxyethyl]phenyl}-3-(3-chlorophenyl)-2-(1,3-dihydro-2Hbenzimidazol-2-ylidene)propane-1,3-dione.

## 6.-11. (canceled).

12. (new): The propane-1,3-dione derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein ring A is benzene which may be substituted with 1 to 3 substituent groups, wherein the substituent groups may be the same or different from each other and each is halogen or lower alkyl.

INTERVIEW Attorney Docket No.: Q96434

Application No.: 10/588,485

13. (new): The propane-1,3-dione derivative or a pharmaceutically acceptable salt thereof according to claim 12, wherein  $R^{401}$  and  $R^{402}$  may be the same or different from each other and each is H, halogen, or lower alkyl.

14. (new): The propane-1,3-dione derivative or a pharmaceutically acceptable salt thereof according to claim 13, wherein  $R^{101}$ ,  $R^{102}$ ,  $R^{103}$  and  $R^{104}$  are each H.

15. (new): The propane-1,3-dione derivative or a pharmaceutically acceptable salt thereof according to claim 4, wherein  $R^{101}$ ,  $R^{102}$ ,  $R^{103}$  and  $R^{104}$  are each H.